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IT has been reported that malignant tumours elaborate a coagulative factor
for their invasive growth (O'Meara and Jackson, 1958; O'Meara, 1958). Prota-
mine sulphate has been found to inhibit the coagulative factor in vitro (Thornes
and O'Meara, 1961) and protamine derivatives have been reported to inhibit the
growth of human cancers (O'Meara and O'Halloran, 1963; Hughes, 1964;
Lutton, 1964). The use of protamine derivatives in the treatment of malignant
disease can cause side effects such as the transient nausea and lassitude noted by
Hughes (1964) using prolothan G and prolothan P. During a clinical trial ofthese
protamine derivatives another side effect became evident, namely tetany.
This paper reports our findings of the effect of prolothan G and prolothan A
on calcium metabolism.
METHODS
We have used two forms of prolothan:
Prolothan G (Evans) is an aqueous solution of protamine standardised to
contain nitrogen 2-5% weight in volume with dextrose 40% weight in volume.
Each 10 ml. ampoule was added aseptically to 500 ml. normal physiological saline
and given as a slow continuous intravenous drip. Initially 10 ml. of prolothan
G are given in the first 24 hours; if nausea did not develop the dosage was raised
to 15 ml. daily and 20 ml. daily after 48 and 72 hours respectively. If nausea
developed the drip was slowed and a drug given (e.g. Fentazin 5 mg. i.m. four
hourly as required).
Prolothan A (Evans) is a complex of protamine with sodium-formaldehyde-
bisulphite in aqueous solution standardised to contain nitrogen 2-5% weight in
volume. It was administered in the same manner as prolothan G.
The weights of prolothan referred to in the text are grams of nitrogen.
Calcium was estimated by flame photometry using Maclntyre's technique,
phosphate by the method ofFiske and Subbarow (1925) and alkaline phosphatase,
plasmasodium, plasmapotassium and total protein bystandardmethods (Wootton,
1964). Radio-isotope counting was done using a thallium-activated sodium iodide
crystal with pulse-height analysis. The patients who were on a controlled calcium
diet were given 20 ,uCi calcium-47 intravenously to measure their calcium blood-
bone dynamics. Blood and urines were collected at predetermined intervals and
the specific activity of the samples measured (Anderson, Osborn. Tomlinson and
Weinbren, 1963).
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RESULTS
The cliniical diagnoses of the fifteen patients investigated together with their
plasma calcium concentrations during prolothan G therapy are given in Table I.
Of the fifteen patients, only one (case 14), who had an initial plasma calcium
concentration of 1458 mg./100 ml., failed to show a lowering of plasma calcium
concentration which was maintained.
Three of the patients (cases 2, 3 and 11) also received intravenous infusions of
prolothan A which was without effect on the plasma calcium concentration
(Fig. 1).
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FIG. 1.--The effects of intravenous prolothan G and prolothan A (in g. daily) on the plasma
calcium and phosphate concentrations in three of the patients.50 J. ANDERSON, R. W. S. TOMLINSON AND J. E. C. WRIGHT
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Figure 2 shows the plasma calcium and phosphorus concentrations and
uriniarv calcium excretion of another three patients (cases 6, 14 and 15) during the
administrationi of prolothan G, after being placed on a standard dietary calcium
iintake of 1000 mg. daily. In cases 6 and 15 there was a decrease in the urinary
calcium excretion after four to five days of prolothan G administration, but case
14 coiitiiiued to excrete about .900 mg. calcium daily during and after prolothan
therapy. 47( a blood-bone dynamics were determined on two of the patients
(cases 6 and 15) during prolothan infusions and the results are shown in Fig. 3.
DISCUSSION
Fourteeni of the patients treated withl prolothan ( showed a fall in their plasma
calcium concentration. The one patient who did not show a sustained decrease
(case 14) lhad hypercalcaemia, without evidence of bone disease. The tolerance of
the patients to prolothan was variable. Three patients developed tetany (cases
1. 3 and 11). In case 3 it lasted a few minutes and responded rapidly to intravenous
calcium gluconate. In cases 1 and 11 the tetany lasted for between one to two
days anid only slowly responded to intravenous calcium in large doses. Calcium
was administered to case 1 on the seventh day and in spite of several injections of
10 g. calciuni gluconate the serum calcium was still low on the ninth day. Other
patients (e.g. case 6) were able to tolerate large doses of prolothan without
developing tetany or any side effects.
The uriniary calcium excretion in two patients who were made hypocalcaemic
with prolothan- Gr did not fall pari passu with the plasma calcium concentration.
The lowest urinary calcium values were found three or four days after the lowest
plasma calcium concentration and in fact the urinary calcium excretion was at its
lowest after the therapy when the plasma calcium concentration was returning to
normal. The 47Ca blood-bone dynamics of the same two patients did not differ
from normal (Anderson, Osborn, Tomlinson and Wall, 1964).
Prolothan A even in large doses did not exhibit the hypocalcaemic effect of
prolothani G. Both prolothan A and prolothan G are aqueous solutions of
protaniine standardised to contain nitrogen 2 50% w/v., the former as a complex
with sodium-formaldehyde-bisulphite, the latter with the addition of 40%w/v
dextrose. It would seem therefore that the complexing with sodium-formalde-
hyde-bisulphite destroys the hypocalcaemic properties of the protamine.
Prolothan G possesses heparin neutralisation properties, whereas prolothan A has
no measurable neutralising effect on heparin.
Protamiine is used clinically as an antidote for excessive heparinisation.
Heparin is also known to be a potent bone resorption factor. Goldhaber (1965)
has reported that heparin markedly enhanced the parathormone, vitamin A,
and vitamin D induced resorption in a tissue culture preparation without having
any appreciable activity alone. It is possible therefore that protamine acts by
blocking the bone resorption enhancement property of heparin, or some other
acid mucopolysaccharide, resulting in hypocalcaemia.
Hypercalcaemia is a frequent complication in patients with malignant tumours
(Woodard, 1953; Swyer, Berger, Gordon andLaszlo, 1950). The hypercalcaemia
observed in patients with skeletal metastases can be explained by destruction of
bone by the tumour with subsequent release of calcium into the blood. Hyper-
calcaemia observed in cases with predominantly osteoblastic metastases or in
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FIG. 2.-The effect of intravenous prolothan G (in g. daily) on the plasma calcium and
phosphate concentrations and the urinary calcium excretion in three patients on a standard
calcium diet.
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whom bone metastases cannot be shown radiologically or at post-mortenm
examination is more difficult to explain. Recently, however. Tashjian, Levine
and Munson (1964) using immunological assay have detected measurable quantities
of parathyroid hormone (or closely related polypeptide) in six tumours associated
with hypercalcaemia without clinical, radiographic or pathological evidence of
bone lesions. Four of our patients (cases 4, 12, 14 and 15) had hypercalcaemia
and of these only one (case 4) had radiological evidence of bone secondaries. Of
the remaining three patients the hypercalcaemia of two (cases 12 and 15)
responded to prolothan G therapy while the hypercalcaemia of case 14 wA,as
unresponsive to the therapy. It would appear from the normal 47Ca blood-boIne
dynamics of the patients studied (cases 6 and 15) that the prolothan G lhad Ino
direct effect on the normal exchange and accretion processes in bone precluding
any acute parathormone blocking action.
Thyrocalcitonin lowers the plasma calcium concentration in patienlts (Foster,
Joplin, Maclntyre, Melvin and Slack, 1966) and it lowers the serum calcium and
serum phosphorus concentrations in the intact animal (Milhaud, Perault and
Moukhtar, 1965). The plasma inorganic phosphorus concentrations in our
patients during prolothan therapy was variable and it is unlikely that the
hypocalcaemia could be attributed to a thyrocalcitonin effect.
The plasma sodium and potassium concentrations remained within normal
limits during prolothan infusion and this excludes a general effect oIn the adrenal
gland. The changes in plasma calcium were not due to changes in plasma proteins
as the total protein concentration was also unaffected during the infusionl. There
was no change in the serum alkaline phosphatase.
The only consistent finding was the hypocalcaemia and its aetiology is uncertain
but it is suggested that it could be due to the inhibition of the bonle resorption
enhancing effect of heparin.
SUMMARY
The effect of prolothan G and prolothan A on calcium metabolism in patienits
with malignancy is described. Therapeutic doses of prolothan G produced
hypocalcaemia in fourteen of the fifteen patients studied. Its possible mode of
action in calcium homeostasis is discussed.
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